European Medicines Agency Validates Type 2 Variation Application For Bristol Myers Squibb's Opdivo (Nivolumab) Plus Yervoy (Ipilimumab) For First-line Treatment Of Microsatellite Instability–High Or Mismatch Repair Deficient Metastatic Colorectal Cancer
European Medicines Agency Validates Type 2 Variation Application For Bristol Myers Squibb's Opdivo (Nivolumab) Plus Yervoy (Ipilimumab) For First-line Treatment Of Microsatellite Instability–High Or Mismatch Repair Deficient Metastatic Colorectal Cancer
歐洲藥品管理局驗證了百時美施貴寶的Opdivo（Nivolumab）Plus Yervoy（Ipilimumab）的2型變異申請，用於一線治療微衛星不穩定性——高度或不匹配的修復缺陷轉移性結直腸癌
European Medicines Agency Validates Type 2 Variation Application For Bristol Myers Squibb's Opdivo (Nivolumab) Plus Yervoy (Ipilimumab) For First-line Treatment Of Microsatellite Instability–High Or Mismatch Repair Deficient Metastatic Colorectal Cancer
歐洲藥品管理局驗證了百時美施貴寶的Opdivo（Nivolumab）Plus Yervoy（Ipilimumab）的2型變異申請，用於一線治療微衛星不穩定性——高度或不匹配的修復缺陷轉移性結直腸癌
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。